From a research point of view, placebos are often essential in determining the safety and efficacy of a treatment. On the other hand, research

From a research point of view, placebos are often essential in determining the safety and efficacy of a treatment. On the other hand, research participants often hope they get active treatment, especially if it is for a disease they already have or might get.

Is it “fair” to research participants to randomly assign them to receive either an active drug or an inactive substance? What about someone with a terminal illness, and the research drug is their last chance? What can be done to make the situation “more fair”?

Share This Post

Email
WhatsApp
Facebook
Twitter
LinkedIn
Pinterest
Reddit

Order a Similar Paper and get 15% Discount on your First Order

Related Questions

  Thank you for sharing your evaluation plans for Harbor Haven Community Services — a vital organization serving a vulnerable population. Your post

  Thank you for sharing your evaluation plans for Harbor Haven Community Services — a vital organization serving a vulnerable population. Your post offers a thoughtful overview of the complex ethical landscape involved in consulting for a social service agency working with individuals experiencing homelessness, mental illness, and substance use